PH12013500403A1 - Fused triazoles for the treatment or prophylaxis of mild cognitive impairment - Google Patents

Fused triazoles for the treatment or prophylaxis of mild cognitive impairment

Info

Publication number
PH12013500403A1
PH12013500403A1 PH1/2013/500403A PH12013500403A PH12013500403A1 PH 12013500403 A1 PH12013500403 A1 PH 12013500403A1 PH 12013500403 A PH12013500403 A PH 12013500403A PH 12013500403 A1 PH12013500403 A1 PH 12013500403A1
Authority
PH
Philippines
Prior art keywords
prophylaxis
treatment
cognitive impairment
mild cognitive
fused triazoles
Prior art date
Application number
PH1/2013/500403A
Other languages
English (en)
Inventor
Yasutaka Hoashi
Yuichi Kajita
Makoto Kamata
Tatsuki Koike
Minoru Nakamura
Takafumi Takai
Yoshihide Tomata
Tetsuya Tsukamoto
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12013500403(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PH12013500403A1 publication Critical patent/PH12013500403A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PH1/2013/500403A 2010-09-02 2011-09-01 Fused triazoles for the treatment or prophylaxis of mild cognitive impairment PH12013500403A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010197064 2010-09-02
JP2011143548 2011-06-28
PCT/JP2011/070419 WO2012029991A1 (en) 2010-09-02 2011-09-01 Fused triazoles for the treatment or prophylaxis of mild cognitive impairment

Publications (1)

Publication Number Publication Date
PH12013500403A1 true PH12013500403A1 (en) 2013-03-25

Family

ID=45094181

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/500403A PH12013500403A1 (en) 2010-09-02 2011-09-01 Fused triazoles for the treatment or prophylaxis of mild cognitive impairment

Country Status (22)

Country Link
US (3) US8822699B2 (enExample)
EP (1) EP2611805A1 (enExample)
JP (1) JP5871909B2 (enExample)
KR (1) KR20130139895A (enExample)
CN (1) CN103249733A (enExample)
AR (1) AR082865A1 (enExample)
AU (1) AU2011296887A1 (enExample)
BR (1) BR112013004746A2 (enExample)
CA (1) CA2809779A1 (enExample)
CL (1) CL2013000575A1 (enExample)
DO (1) DOP2013000051A (enExample)
EA (1) EA201390333A1 (enExample)
EC (1) ECSP13012535A (enExample)
MA (1) MA34556B1 (enExample)
MX (1) MX2013002511A (enExample)
PE (1) PE20131305A1 (enExample)
PH (1) PH12013500403A1 (enExample)
SG (1) SG187917A1 (enExample)
TW (1) TW201213327A (enExample)
UY (1) UY33586A (enExample)
WO (1) WO2012029991A1 (enExample)
ZA (1) ZA201301929B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767764A1 (en) * 2009-07-13 2011-01-20 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
MX2013002511A (es) * 2010-09-02 2013-07-29 Takeda Pharmaceutical Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
RU2563254C2 (ru) * 2013-07-08 2015-09-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения производных 7-(гетеро)арил-4,5,6,7-тетрагидро[1,2,3]триазоло[1,5-a]пиридина
CA2980643C (en) * 2015-05-12 2023-10-17 E I Du Pont De Nemours And Company Aryl substituted bicyclic compounds as herbicides
US20210079182A1 (en) * 2019-09-12 2021-03-18 Dupont Electronics, Inc. Polyimide films and electronic devices
CA3240896A1 (en) * 2021-12-17 2023-06-22 Athira Pharma, Inc. Uses of bicyclic compounds for the treatment of diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2395862A1 (en) 2000-02-17 2001-08-23 Hong Liu Succinoylamino carbocycles and heterocycles as inhibitors of a.beta. protein production
MXPA05012281A (es) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
ES2356356T3 (es) * 2003-10-15 2011-04-07 Targacept, Inc. Compuestos azabicíclicos para aliviar el dolor y tratar los trastornos del sistema nervioso central.
BRPI0511504A (pt) 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
ATE458729T1 (de) 2004-10-26 2010-03-15 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
WO2007081897A2 (en) 2006-01-11 2007-07-19 Merck & Co., Inc. Fused triazole tachykinin receptor antagonists
WO2007102580A1 (ja) 2006-03-09 2007-09-13 Eisai R & D Management Co., Ltd. 多環式シンナミド誘導体
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
US8143394B2 (en) 2006-12-26 2012-03-27 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infections
EP2119719A1 (en) 2006-12-26 2009-11-18 Daiichi Sankyo Company, Limited Thiazepine derivative
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
JP2011506335A (ja) 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2010197064A (ja) 2009-02-23 2010-09-09 Chugoku Electric Power Co Inc:The 直下位置測定装置
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
CN102333777B (zh) 2009-02-26 2014-06-25 卫材R&D管理有限公司 含氮的稠合杂环化合物及其作为β淀粉样蛋白生成抑制剂的用途
JP2012051806A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
WO2011002067A1 (ja) 2009-07-02 2011-01-06 武田薬品工業株式会社 複素環化合物およびその用途
CA2767764A1 (en) * 2009-07-13 2011-01-20 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
ES2519565T3 (es) 2009-07-15 2014-11-07 Janssen Pharmaceuticals Inc. Derivados de triazol e imidazol sustituidos como moduladores de gamma secretasa
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
WO2011016559A1 (ja) 2009-08-07 2011-02-10 武田薬品工業株式会社 複素環化合物およびその用途
JP2011143548A (ja) 2010-01-12 2011-07-28 Panasonic Corp スクリーン印刷機及びスクリーン印刷方法
WO2011086098A1 (en) 2010-01-15 2011-07-21 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted bicyclic triazole derivatives as gamma secretase modulators
MX2013002511A (es) * 2010-09-02 2013-07-29 Takeda Pharmaceutical Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.

Also Published As

Publication number Publication date
DOP2013000051A (es) 2013-04-30
CN103249733A (zh) 2013-08-14
US20130178497A1 (en) 2013-07-11
TW201213327A (en) 2012-04-01
JP2013536798A (ja) 2013-09-26
ECSP13012535A (es) 2013-06-28
AR082865A1 (es) 2013-01-16
AU2011296887A1 (en) 2013-04-11
CA2809779A1 (en) 2012-03-08
UY33586A (es) 2012-03-30
ZA201301929B (en) 2013-11-27
US8901309B2 (en) 2014-12-02
EA201390333A1 (ru) 2013-08-30
US20120059030A1 (en) 2012-03-08
MA34556B1 (fr) 2013-09-02
JP5871909B2 (ja) 2016-03-01
US20140350260A1 (en) 2014-11-27
MX2013002511A (es) 2013-07-29
PE20131305A1 (es) 2013-10-31
BR112013004746A2 (pt) 2016-06-07
KR20130139895A (ko) 2013-12-23
SG187917A1 (en) 2013-04-30
WO2012029991A1 (en) 2012-03-08
CL2013000575A1 (es) 2013-08-23
EP2611805A1 (en) 2013-07-10
US8822699B2 (en) 2014-09-02

Similar Documents

Publication Publication Date Title
PH12013501099A1 (en) Bicyclic compound
TN2012000401A1 (en) Heterocyclic compound
PH12014500759A1 (en) 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
IN2014CN04558A (enExample)
EA201590661A1 (ru) Азахиназолиновые ингибиторы атипичной протеинкиназы c
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
IN2015DN00827A (enExample)
AU2012324805A8 (en) (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
MX2014002442A (es) Inhibidores de pirrolopirazina cinasa.
PH12014502396B1 (en) Nitrogenated heterocyclic compound
PH12013500403A1 (en) Fused triazoles for the treatment or prophylaxis of mild cognitive impairment
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
MY189098A (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
MX353062B (es) Nuevas carboxamidas heterociclicas como moduladores de la activadad de cinasas.
GEP20156399B (en) Microbiocidal heterocycles
TN2013000074A1 (en) Fused triazoles for the treatment or prophylaxis of mild cognitive impairment
IN2012DN02069A (enExample)
CR20130119A (es) Triazoles fundido para el tratamiento o profilaxis de deterioro cognitivo leve
TN2013000230A1 (en) Bicyclic compound
UA58679U (ru) 8-оксихинолиния нитробензоаты, которые проявляют противовоспалительную и антимикробную активность
UA109932C2 (xx) Циклопропіламіни як інгібітори lsd1
GEP201606554B (en) Nitrogenated heterocyclic compound
MX2014002343A (es) Inhibidores de parp.